Evidence map›Paper›PMID 32354922›Full record

ArticleIn vivo (Athens, Greece)

BIT-ART: Multicentric Comparison of HDR-brachytherapy, Intensity-modulated Radiotherapy and Tomotherapy for Advanced Radiotherapy in Prostate Cancer.

Anna Rita Alitto, Luca Tagliaferri, Valentina Lancellotta, Andrea D'Aviero, Antonio Piras, Vincenzo Frascino, Francesco Catucci, Bruno Fionda, Christian Staackmann, Simonetta Saldi and 4 more

Open access · diamondAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Anna Rita AlittoFondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Luca TagliaferriFondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Valentina LancellottaFondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy valentina.lancellotta@policlinicogemelli.it.
Andrea D'AvieroUniversità Cattolica del Sacro Cuore, Rome, Italy.
Antonio PirasUniversità Cattolica del Sacro Cuore, Rome, Italy.
Vincenzo FrascinoFondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Francesco CatucciFondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Bruno FiondaFondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Christian StaackmannInterdisciplinary Brachytherapy Unit, University of Lübeck - University Hospital S-H, Campus Lübeck, Lübeck, Germany.
Simonetta SaldiRadiation Oncology Section, Department of Surgery and Biomedical Science, University of Perugia, Perugia, Italy.
Vincenzo ValentiniFondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Gyorgy KovacsInterdisciplinary Brachytherapy Unit, University of Lübeck - University Hospital S-H, Campus Lübeck, Lübeck, Germany.
Cynthia AristeiRadiation Oncology Section, Department of Surgery and Biomedical Science, University of Perugia, Perugia, Italy.
Giovanna MantiniFondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Agostino Gemelli University Polyclinic · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Perugia · ITUniversity of Lübeck · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe aim of the study was to evaluate acute and late genitourinary (GU) and gastrointestinal (GI) toxicity in patients with high- or intermediate-risk prostate cancer. PATIENTS AND

methodsWe evaluated data of patients from three Radiation Oncology Departments (Rome, Lübeck and Perugia). Patients treated in Rome underwent exclusive intensity-modulated-radiotherapy (IMRT) or IMRT plus high-dose-rate interventional radiotherapy (HDR-IRT). IMRT plus two fractions HDR-IRT was performed in Lübeck, while in Perugia Helical Tomotherapy was performed. The Common Toxicity Criteria for Adverse Event (Version 4.03) scale was used to describe acute and late toxicity.

resultsAt a median follow-up of 28 months, all 51 patients were alive and disease-free. Patients treated by HDR-IRT plus VMAT showed only G1-2 genitourinary- gastrointestinal (GU-GI) acute and late toxicity. Univariate analysis showed a lower risk of acute GU toxicity (p=0.048) in IMRT+HDR-IRT.

conclusionLow grade and less acute GU toxicity was observed in patients undergoing HDR-IRT boost.

Indexed as

BrachytherapyRadiotherapy DosageRadiotherapy, Intensity-ModulatedTomography, Spiral ComputedAgedAged, 80 and overDisease ManagementDose Fractionation, RadiationHumansMaleMiddle AgedNeoplasm GradingNeoplasm StagingProstatic NeoplasmsRadiotherapy Planning, Computer-AssistedRecurrencefocal therapyHDR brachytherapyhelical tomotherapyPersonalized medicineprostate cancertoxicityVMAT

Identifiers

PMID32354922
PMCPMC7279807
OpenAlexW3023028473

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.